Talphera Inc (TLPH)

03:18 AM

HC Wainwright Estimates Talphera FY2029 Earnings - Defense World

03:18 AM

Apr 03, 2025

Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks

Apr 03, 2025

Apr 03, 2025

Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com Canada

Apr 03, 2025

Apr 03, 2025

Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com

Apr 03, 2025

Apr 02, 2025

Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World

Apr 02, 2025

Apr 01, 2025

Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks

Apr 01, 2025

Apr 01, 2025

H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada

Apr 01, 2025

Apr 01, 2025

H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India

Apr 01, 2025

Apr 01, 2025

Talphera: Q4 Earnings Snapshot - CT Insider

Apr 01, 2025

Apr 01, 2025

Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance

Apr 01, 2025

Mar 31, 2025

Talphera Reports 2024 Financial Results and Study Update - TipRanks

Mar 31, 2025

Mar 31, 2025

Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN

Mar 31, 2025

Mar 31, 2025

Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India

Mar 31, 2025

Mar 31, 2025

FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK

Mar 31, 2025

Mar 31, 2025

TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

TALPHERA, INC. SEC 10-K Report - TradingView

Mar 31, 2025

Mar 31, 2025

Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025

Mar 31, 2025

FDA approves Talphera’s reduced NEPHRO CRRT study size - Investing.com India

Mar 31, 2025

Mar 31, 2025

Talphera reports Q4 EPS (7c) vs. (25c) last year - TipRanks

Mar 31, 2025

Mar 31, 2025

FDA Green Light: Talphera Slashes Trial Size by 58% as Q4 Losses Drop 57% - Stock Titan

Mar 31, 2025

Mar 31, 2025

TLPH stock touches 52-week low at $0.5 amid market challenges - Investing.com

Mar 31, 2025

Mar 31, 2025

Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall - MarketScreener

Mar 31, 2025

Mar 31, 2025

Talphera Scores Major FDA Win: NEPHRO Study Size Slashed by 58% While Securing $14.8M Backing - Stock Titan

Mar 31, 2025

Mar 28, 2025

Earnings Outlook For Talphera - Benzinga

Mar 28, 2025

Mar 26, 2025

Talphera to Unveil 2024 Performance: Key Financial Results and Strategic Updates Coming March 31 - Stock Titan

Mar 26, 2025

Mar 14, 2025

Talphera Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Mar 14, 2025

Mar 03, 2025

Talphera (TLPH) Expected to Announce Earnings on Wednesday - Defense World

Mar 03, 2025

Feb 27, 2025

Talphera chief medical officer Aslam Shakil purchases $6,038 in stock By Investing.com - Investing.com South Africa

Feb 27, 2025

Feb 26, 2025

Talphera chief medical officer Aslam Shakil purchases $6,038 in stock - Investing.com

Feb 26, 2025

Feb 22, 2025

Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened - Armenian Reporter

Feb 22, 2025

Feb 17, 2025

Talphera Inc (NASDAQ: TLPH) Is On The Rise - Stocks Register

Feb 17, 2025

Jan 30, 2025

RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy - Defense World

Jan 30, 2025

Jan 28, 2025

Rodman & Renshaw sets Talphera stock Buy rating, $4 target - MSN

Jan 28, 2025

Jan 22, 2025

Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright - Defense World

Jan 22, 2025

Jan 14, 2025

FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada

Jan 14, 2025

Jan 14, 2025

FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria

Jan 14, 2025

Jan 14, 2025

FDA to review Talphera's request to amend NEPHRO study - Investing.com

Jan 14, 2025

Jan 14, 2025

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online

Jan 14, 2025

Jan 14, 2025

Talphera's NEPHRO CRRT Study Gains FDA Backing for Accelerated Patient Enrollment - Stock Titan

Jan 14, 2025

Dec 26, 2024

TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK

Dec 26, 2024

Dec 17, 2024

TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com

Dec 17, 2024

Dec 12, 2024

Talphera faces Nasdaq delisting over share price rule - Investing.com

Dec 12, 2024

Dec 11, 2024

Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK

Dec 11, 2024

Dec 11, 2024

Acelrx Announces Dsuvia® Milestone C Approval; Provides Revenue Guidance for the First Quarter 2020 - Marketscreener.com

Dec 11, 2024

Dec 07, 2024

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 - Kilgore News Herald

Dec 07, 2024

Dec 06, 2024

Talphera CEO Vincent J. Angotti acquires $3,199 in common stock - Investing.com

Dec 06, 2024

Dec 06, 2024

Talphera CEO Vincent J. Angotti acquires $3,199 in common stock By Investing.com - Investing.com UK

Dec 06, 2024

Dec 02, 2024

Talphera CEO Vincent J. Angotti buys $3,649 in company stock By Investing.com - Investing.com Canada

Dec 02, 2024

Dec 02, 2024

Talphera CFO Raffi Asadorian sells shares worth $118 - Investing.com India

Dec 02, 2024

Dec 02, 2024

Talphera CEO Vincent J. Angotti buys $3,649 in company stock - Investing.com India

Dec 02, 2024

Dec 02, 2024

Talphera CFO Raffi Asadorian sells shares worth $118 By Investing.com - Investing.com Canada

Dec 02, 2024